RET and medullary thyroid gland carcinoma: In the phase 3 study EXAM, Cabozantinib (140 mg) was used in progressive and metastatic RET M918T MTC and although the significant difference of PFS (11.2 months vs. 4 months, refs. [35,36]), the severe observed adverse effects in advanced MTC patients led to dose reduction or dose discontinuation; thus, Cabozantinib has been indicated as second-line treatment.